Japanese T2DM patients were enrolled in a prospective , randomized , open-label , blinded-end point study and received pioglitazone with or without other oral glucose-lowering drugs ( excluding another thiazolidinedione [ TZD ] ) ( n = 293 ) or oral glucose-lowering drugs excluding TZD ( n = 294 ) .